DiaMedica Therapeutics Inc.
NASDAQ:DMACBiotechnology
-$0.01 today
- Market cap
- $463.49M
- Beta
- 1.00
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$0.65
Volume 0.21M
Average 0.19M
DMAC Short-term Investments
Marketable securities and deposits the company expects to convert to cash within a year.
DiaMedica Therapeutics Inc.NASDAQ: DMAC
Short-term Investments · Q1 FY2026 · quarter ended Mar 2026
Short-term investments rises 37.7% from a year ago
Short-term investments stood at $46.46M at the end of Q1 FY2026, up 37.7% from a year earlier and up 5.0% from the prior quarter. Over 3 fiscal years it compounded at +15.4% a year.
Context
- Short-term investments amounted to 87.5% of total assets at the end of Q1 FY2026, up 0.7 pp from a year earlier.
- Short-term investments increased in 2 of the last 3 fiscal years.
What to watch
Whether short-term investments keeps rising in the next quarterly balance sheet after a +37.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 44.24M USD
- Year-over-year change
- +7.6%
- 4-year CAGR
- +2.3%
| Period | Period end | Short-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 44.24M | +7.6% |
| FY2024 | 2024-12-31 | 41.12M | -15.0% |
| FY2023 | 2023-12-31 | 48.35M | +68.0% |
| FY2022 | 2022-12-31 | 28.77M | -28.8% |
| FY2021 | 2021-12-31 | 40.41M | — |
Short-term Investments vs competitors
How DMAC compares with its peers on the latest reported figures
- DMAC's Mar 2026 short-term investments of $46.46M is the 5th highest of the 7 companies compared; the peer median is $132.23M.
- Its year-over-year change of +37.7% is the 2nd highest of 4, against a peer median of -32.8%.
- Short-term investments amounts to 87.5% of total assets for DMAC, versus a peer median of 36.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $508.94M | -32.8% | -16.0% | 44.0% | |
| Mar 2026 | $153.62M | — | — | 36.6% | |
BIOABioAge Labs, Inc. | Mar 2026 | $141.42M | +124.4% | — | 35.6% |
| Mar 2026 | $123.05M | -46.7% | — | 42.0% | |
| Mar 2026 | $46.46M | +37.7% | +15.4% | 87.5% | |
| Mar 2026 | $17.22M | — | — | 26.7% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding DMAC) | $132.23M | -32.8% | -16.0% | 36.1% | |
Competitors are the stored peer set for DMAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
DiaMedica Therapeutics Inc.
NASDAQ:DMAC
Intrinsic Alpha fair value
Locked
Current Price
$8.59
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.